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Abstract 
The article presents the results of a comparative analysis of different therapy regimens impact on the 
effectiveness of treatment of patients with early and late rheumatoid arthritis in steady-state. Data on ongoing 
basis anti-inflammatory therapy of rheumatoid arthritis and the treatment of associated conditions were obtained 
by continuous copying from case histories of hospital department patients. The observations lasted 12 months. 
The activity of rheumatoid arthritis before and after the treatment was determined by the DAS 28 (Disease Activity 
Score) index. The treatment results were evaluated as per the laboratory research and the DAS 28 index, 
including the counting of painful and swollen joints, erythrocyte sedimentation rate, and health assessment of the 
patient on a visual analogue scale. 
 
 
 
 
 
 
 
 
 
Introduction 
 
Rheumatoid arthritis (RA) is one of the most 
severe and frequent inflammatory rheumatic diseases, 
which is associated with progression of joint 
destruction, decreased functional capacity and quality 
of life of patients, and the socio-economic hardship is 
occurring in this context [1]. 
Rheumatic diseases occur in people of any 
age, starting with children, but have a clear tendency 
to a significant accumulation with increasing age of 
patients. In the Russian Federation, up to 700 
thousand new cases of inflammatory and 
degenerative diseases of the joints and systemic 
diseases of the connective tissue are diagnosed for 
the first time every year [2], [3]. The peak of the RA 
debut falls mainly on the working age. The loss of 
functional activity due to the development of erosive 
and destructive changes in the joints leads to disability 
and incapacitation of patients. Ten years after the 
onset of the disease, 67% of patients have high (II – 
III) functional insufficiency of the joints and 44.5% 
have I and II disability groups [4]. The medical 
community considers rheumatic diseases as risk 
factors for the development of severe associated 
chronic diseases [3], [5]. The accelerated 
development of cardiovascular and other diseases in 
RA leads to reduced life expectancy and increased 
levels of mortality by 50 – 60% as compared to the 
general population. These are the rheumatic diseases 
that make the greatest contribution to the reduction of 
efficiency, deterioration of the general health of the 
population. All this causes a heavy socio-economic 
burden of this disease both for the patients, 
significantly reducing the quality of their life, and for 
the state health system as a whole due to the required 
considerable financial expenses for the provision of 
medical and pharmaceutical care to patients [5], [6], 
[7]. 
Pashanova et al. Comparative Analysis of Approaches and Treatment Results of Patients with Early and Nonearly Rheumatoid Arthritis 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2019 Sep 15; 7(17):2802-2806.                                                                                                                                                2803 
 
Literature Review 
Currently, the concept of managing patients 
with RA includes early diagnosis of the disease, timely 
active treatment commenced with the implementation 
of a therapeutic window of opportunity, careful 
monitoring for RA and response to therapy, the 
maximum suppression of disease activity in the short 
term in order to achieve and maintain a state of 
remission that is aimed at preventing the decline of 
patients' quality of life (program of "Treatment to reach 
the target") [8], [9], [10]. 
The primary method of achieving and 
increasing the duration of the RA remission stages is 
long-term use of the disease-modifying anti-rheumatic 
drugs (DMARD) and genetically engineered biologic 
drugs (GEBD), which reduce the activity of the 
inflammatory and autoimmune process. A large 
number of publications of domestic and foreign 
authors devoted to various approaches to the RA 
treatment confirm that the application of this approach 
in the RA treatment has resulted in tremendous 
progress [11], [12], [13], [14], [15], [16], [17], [18], [19], 
[20]. 
However, as noted by rheumatologists, the 
disease is the most important socio-economic 
problem because of its high incidence, poor prognosis 
(at untimely and inadequate treatment), as well as the 
need for long-term, and sometimes permanent, 
administration of different combinations of drugs. 
Moreover, a significant proportion of patients' needs 
orthopaedic surgery. The modern approaches to RA 
treatment are associated with significant financial 
costs. The above explains the significant socio-
economic losses associated with RA that were similar 
to those seen in ischemic heart disease [4], [15], [16]. 
According to the data of Sh.F. Erdos, D.V. 
Goryacheva, O.A. Grigoriev et al., as a result of a 
clinical and economic study, it was revealed that the 
failure to obtain a social product due to the temporary 
disability of patients with RA was, on average, EUR 1 
million/year in Russia. The support of one disabled 
person from the moment of disability until death costs 
the state EUR 20.4 thousand. The total state 
expenditures for disabled people with RA are EUR 18 
billion. At the same time, the state does not receive a 
profit for EUR 160.5 thousand to EUR 214.0 thousand 
per each disabled person [21], [22]. 
The evaluation of the economic impact of two 
diseases of the musculoskeletal system and 
connective tissue, namely the RA and ankylosing 
spondylitis, showed that the value of direct medical 
costs was equal to EUR 6,454 per year (medical costs 
– EUR 4,170 per year, nonmedical costs – EUR 2,284 
per year). The indirect costs due to disability 
constitute EUR 6,447 per year [22].  
The cost of treatment and examination of the 
patient for the state is only 1/3 of the costs associated 
with RA. The remaining costs are determined by a 
decrease in the quality of life of patients, the 
termination of their contribution to the creation of the 
common national product, and a decrease in the 
labour activity of relatives to provide care for the 
patient [22], [23], [24], [25]. 
The financial situation is an important factor 
that affects the performance associated with quality of 
life, including the functional activity of the patient [25], 
[26], [27]. 
Since RA is a chronic disease, and in fact, 
patients need expensive drugs for the life term, 
strategic approach to treatment is required. 
 
 
Methods 
 
The content analysis of publications of 
domestic and foreign authors, the methods of 
mathematical statistics, structural, correlation, the 
nonparametric analysis were used in the process of 
work. 
Statistica 6.0 (Statsoft, USA) was used for 
statistical data processing. The results are presented 
in the form of a median and interquartile interval (Me 
[25th; 75th percentile]). To compare the frequencies of 
qualitative traits in groups, the χ2 criterion was used. 
When comparing the groups, the Mann-Whitney U 
test was used, and the correlation analysis was 
performed using the Spearman's Rank-Order 
Correlation. Differences were considered significant at 
p < 0.05. RA activity was determined from the DAS 28 
value recommended by the European League Against 
Rheumatism (EULAR) as follows: DAS 28 > 5.1 – first 
class of activity, DAS 28 [3,2;5,1] – second class of 
activity, DAS 28 [2,6;3,2] – third class of activity, and 
DAS 28 < 2.6 – remission [28], [29]. 
 
 
Results 
 
The study included data on the results of 
treatment in 200 patients with a definite diagnosis of 
RA (165 women and 35 men) aged 19 to 73 years 
who had been treated in a special hospital. 
Table 1: The structure of the cohort of patients included in the 
study (n = 200) 
Indicator Value 
Gender, female/male, of them: 
Women from 19 to 55 years old, n (%) 
Women over 55 years old, n (%) 
Men from 26 to 60 years old, n (%) 
Men over 60 years old, n (%) 
165/35 or 4.7:1 
79 (47.9) 
86 (52.1) 
27 (77.1) 
8 (22.9) 
 
As can be seen from Table 1, almost half 
(47.9%) of the women and the majority (77.1%) of the 
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men suffering from RA were in working age. 
One hundred and forty four patients (72.0%) 
had concomitant diseases, with arterial hypertension 
most commonly occurring – 60.0%, dyslipidemia – 
45.0%, fractures of various localization – 29.5%, 
coronary heart disease – 21.0%, and also myocardial 
infarction (1.5%), stroke (1.0%), diabetes mellitus 
(7.5%), osteoporosis (15.5%), and ulcerative lesions 
of the upper gastrointestinal tract (14.9%). 
Using continuous copying from the case 
histories, information on the medical prescription of 
drugs to the population of patients under study was 
obtained. Methotrexate was administered as the main 
DMARD; 139 (69.5%) patients received it. 
Leflunomide (9.0%) and sulfasalazine (1.5%) were 
also used. The GEBD therapy was used in 21.5% of 
cases and was represented by TNF-alpha inhibitors 
(9.0%), rituximab (6.5%), abatacept (4.5%), and 
tocilizumab (1.0%). Nineteen patients (9.5%) received 
nonsteroidal anti-inflammatory drugs (diclofenac, 
nimesulide, and meloxicam), 95 (47.5%) patients – 
selective COX-2 inhibitors (etoricoxib), and 86 (43%) 
patients – glucocorticoids (methylprednisolone, 
prednisone).  
Additional therapy was assigned for the 
treatment of associated diseases. Ninety-eight 
(81.7%) of 120 patients received antihypertensive 
drugs; 27 (22.5%) patients – statins; 12 (10%) 
patients – hypoglycemic therapy; and 27% of the total 
number of patients received low doses of aspirin. 
For a comparative analysis of the approaches 
and results of treatment of patients with early and 
nonearly RA, the patients were divided into two 
groups as follows (Table 2): the first one – with early 
RA (eRA) with a disease duration of up to two years 
(n = 60), the second included the patients with 
nonearly RA (more than two years) (nRA) (n = 140). 
The patient groups were matched by age, sex, and 
RA activity. 
Table 2: Characteristics of patient groups prior to observation 
Indicator eRA value nRA value 
Gender, female/male (%), of them: 
Women from 19 to 55 years old, n (%) 
Women over 55 years old, n (%) 
Men from 26 to 60 years old, n (%) 
Men over 60 years old, n (%) 
49/11 (82) 
22 (36.7) 
27 (45) 
10 (16.7) 
1 (1.6) 
116/24 (83) 
42 (30) 
74 (52.9) 
17 (12.1) 
7 (5) 
Disease duration, years 
Me [25th; 75th percentile] 
0.7 [0.3; 1.2] 8 [4; 14] 
Activity, n (%): I/II/III 28/39/33 31/54/15 
DAS 28, Me [25th; 75th percentile] 4.23 [3.1; 5.7] 3.8 [3.1; 4.7] 
 
Methotrexate was prescribed to most patients 
as basic therapy: in the first group – to 49 patients 
(81.7%) at a dose of 20 [15; 25] mg/week, in the 
second group – to 90 (64.3%) patients at a dose of 15 
[10; 20] mg/week. All patients treated with 
methotrexate also received folic acid at a dose of 4.5 
[3,3; 10.0] mg/week. Two (3.3%) patients of the first 
group and 16 (11.4%) patients of the second group 
received leflunomide; one patient (1.6%) of the first 
group and two (1.4%) patients of the second group 
received sulfasalazine. Twelve (20%) patients with 
eRA and 31 (22%) patients with nRA received GEBD. 
The frequency of assigning various GEBD is 
presented in Table 3. More than half of the patients 
were additionally administered NSAIDs, of which two 
(3.3%) patients of the first group and 17 (12%) 
patients of the second group received nonselective 
NSAIDs, 32 (53.3%) patients of the first group and 63 
(45.0%) patients of the second group received 
selective NSAIDs. 
Table 3: The frequency of use of drugs for the RA treatment in 
patients with eRA (n = 60) and with nRA (n = 140) 
Name of the drug Assignment frequency, n (%) 
eRA nRA 
Methotrexate 49 (81.7) 90 (64.3) 
Leflunomide 2 (3.3) 16 (11.4) 
Sulfasalazine 1 (1.6) 2 (1.4) 
GEBD: 
Adadimumab 
Certolizumab 
Infliximab 
Tocilizumab 
Rituximab 
Abatacept 
12 (20) 
8(13.3) 
2 (3.3) 
- 
- 
- 
2 (3.3) 
31 (22) 
5 (3.6) 
1 (0.7) 
3 (2.1) 
2 (1.4) 
13 (9.3) 
7 (5) 
NSAID, of them: 
- nonselective 
- selective 
34 (56.6) 
2 (3.3) 
32 (53.3) 
80 (57.0) 
17 (12.0) 
63 (45.0) 
 
The patients had been monitored for 12 
months. By the end of the study, 26 patients were 
selected of which three had died, 13 had refused 
further research, and eight had not taken drugs for 
various reasons (pregnancy, high cost, and patient 
reluctance). 
The results of the therapy were evaluated 
after 12 months in 56 patients with eRA and 128 
patients with nRA. The characteristics of the patients 
are presented in Table 4. No differences have been 
found between weight and disease activity in groups 
of patients with eRA and nRA after 12 months. 
Table 4: Characteristics of patients after 12 months of 
treatment 
Indicator eRA (n = 56) nRA (n = 128) 
DAS 28, points 3.0 [2.3; 4.4] 3.5 [2.6; 4.5] 
Activity, remission/I/II/III, n 13/15/22/6 14/36/61/17 
 
In general, in the eRA group, after 12 months, 
a decrease in the disease activity was observed as 
evidenced by the dynamics of the DAS 28 level from 
4.23 to 3.0 points (p = 0.01), as well as a decrease in 
the number of patients with a third (III) degree of 
activity (from 33 to 6 people), and identification of the 
stage of drug remission in 13 patients (p < 0.01). In 
the nRA group, there was a tendency to a decrease in 
the level of DAS 28 from 3.8 to 3.5 points (p = 0.06). 
As a result of analyzing the effect of drug 
combinations on the DAS 28 index, it was found that 
only the patients receiving combinations with GEBD 
had shown a significant decrease in DAS 28. 
Rituximab in the first group significantly reduced DAS 
28 (n = 15, p = 0.04) from 4.5 [3.5; 5.3] to 3.8 [3.0; 
4.4]. In the second group of patients (n = 14), the 
reliability of the results decreased (p = 0.06). 
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To verify the data obtained, a parallel study 
was conducted. It included data on the treatment of 64 
patients with RA (54 women and 10 men) aged 55 
[48; 60] years, with a prolonged course of the disease 
(5 [1 – 10] years), with moderate and high clinical 
disease activity (DAS 28 = 4.5 [3.5 – 5.3]). All patients 
received GEBD: tumor necrosis factor-α inhibitors 
(TNF-α) were used in 27/64 (42%) patients, rituximab 
– in 15/64 (23%) patients, abatacept – in 12/64 (19%) 
patients, and tocilizumab – in 10/64 (16%) patients. 
Therapy with DMARDs was carried out in all patients. 
The patients were monitored for 12 months, and the 
disease activity was assessed by DAS 28.  
As a result of the analysis of the GEBD 
influence on the DAS 28 index, a significant decrease 
in the index from 4.5 [3.5 – 5.3] to 3.7 [2.5; 4.6], p < 
0.01 was revealed. The most significant decrease in 
the DAS 28 index was observed during therapy with 
rituximab (4.5 [3.5; 5.3] and 3.8 [3.0; 4.4], p = 0.04). 
The results are consistent with the research of R.M. 
Balabanova, V.N. Amirjanova, E.L. Nasonova, D.V. 
Goryacheva [13], [30]. 
According to the results of the clinical studies, 
a decrease in the level of C-reactive protein and 
rheumatoid factor by 73% and 59%, respectively, was 
observed in the studied group of patients. It was found 
that the most significant reduction in the average 
values of these indicators was typical for the patients 
whom rituximab was administered. 
 
 
Discussion 
 
As noted above, the indicator of the quality of 
life is largely determined by the financial situation of 
the RA patient. For treatment, each patient with RA 
must be hospitalised once a year for 10 – 21 days (the 
average cost of hospitalisation is RUB 50,000 (EUR 
687.54), and make blood tests once a month (RUB 
500/month; RUB 6,000/year); the cost of each 
injection of the drug is about RUB 1,000. Direct 
medical expenses of the patient for the treatment will 
amount to RUB 58,000 – 128,000 (EUR 798 – 1,760) 
per year, excluding the cost of drugs.  
The total direct costs for RA therapy using 
methotrexate and leflunomide regimens will be RUB 
58,714 – 209,265 (EUR 807 – 2,878), respectively. 
However, these regimens do not have a significant 
effect on reducing RA activity. 
GEBD therapy is 3 – 5 times more expensive 
due to the high cost of the GEBD (EUR 2,550 – 
15,365). These therapy regimens reliably reduce the 
DAS 28 index, increase the frequency of remissions 
almost two times, compared to traditional therapy; 
therefore, improve the quality of life of patients. The 
frequency of deaths with strategies with the use of 
GEBD decreases by more than 10% in ten years [26]. 
In conclusion, the comparative analysis of 
different approaches to the treatment of RA has 
revealed a significant decrease of DAS 28 using 
rituximab (4.5→3.8). At the same time, the total direct 
cost of the RA therapy with rituximab is significantly 
lower than that in the treatment of RA using other 
GEBD. The GEBD treatment is especially important 
for patients with the nRA, more than half of whom are 
pensioners. Even the minimum direct cost of the RA 
therapy is 1.4 times higher than the average old-age 
retirement pension in Russia. For working people, the 
total direct costs for the GEBD therapy are 53.4 – 
82.0% of the average wage. 
It is obvious that the average citizen of Russia 
cannot afford the GEBD treatment; therefore, the main 
burden of using biological products must be taken by 
the state budget, which has significant limitations for 
carrying out expensive therapies. For the sustainable 
use of limited budgetary funds in medical 
organizations of the state healthcare system in 
Moscow, a commission has been set up to monitor 
the treatment using GEBD. 
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